The Treatment of Obesity – FDA Approves BELVIQ XR ER

Published Date: July 20, 2016

On July 19, Eisai, Inc., and Arena Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) approved BELVIQ XR (lorcaserin HCl) CIV extended-release 20 mg tablets for the treatment of obesity. Previously the FDA approved a 10 mg, twice-daily tablet for obesity treatment use with a reduced-calorie diet and increased physical activity for adults with obesity. The new formulation approved today will offer patients a once-a-day option for obesity treatment, weight loss, and weight maintenance.

Learn More

Comments are closed.